Current antiviral therapies are insufficient for treating emerging, re-emerging and established viral diseases. In an effort to find new therapeutics, oligo- and polyribonucleotides are being studied for their antiviral capabilities. Studies have shown that uniquely modified single- and double-stranded nucleic acid constructs are effective in inhibiting viral proliferation by various mechanisms. This review gives a brief history and highlights the development of oligo- and polyribonucleotides as antiviral agents primarily in the fields of interferon induction, mRNA complementation and reverse transcriptase inhibition.
AbdouSCollombJSallasFMarsuraA & FinanceC (1997) Betacyclodextrin derivatives as carriers to enhance activity of an antisense oligonucleotide directed towards a coronavirus intergenic consensus sequence. Archives of Virology142: 1585–1602.
2.
Aboul-FadlTAgrawalVKBuckheitRW & BroomAD (2004) An unusual ‘senseless’ 2′-5′-oligonucleotide with potent anti-HIV activity. Nucleosides, Nucleotides & Nucleic Acids23: 545–554.
3.
AbsherM & StinebringWR (1969) Endotoxin-like properties of PolyI.Poly C, an interferon stimulator. Nature223: 715–717.
4.
Alvarez-SalasLMBenitez-HessML & DiPaoloJA (2003) Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses. Antiviral Therapy8: 265–278.
5.
AnHWangTMaioerMAManoharanMRossBS & CookPD (2001) Synthesis of novel 3′-C-methylene thymidine and 5-methyluridine/cytidine H-phosphonates and phosphanamidites for new backbone modifications of oligonucleotides. Journal of Organic Chemistry66: 2789–2801.
6.
AnazodoMIWainbergMAFriesenAD & WrightJA (1995) Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. Journal of Virology69: 1974–1801.
7.
ArmstrongJAMcMahonDHuangXLPazinGJGuptaPRinaldoCIJrSchoenfeldDAGaccionePTripoliCABensasiS & HoM (1992) A phase I study of ampligen in human immunodeficiency virus-infected subjects. Journal of Infectious Diseases166: 717–722.
8.
AryaSKHelserTL & CarterWA (1976) Polyxanthylic and polyguanylic acid inhibition of murine leukemia virus activities. Molecular Pharmacology12: 844–853.
9.
Astriab-FisherAFisherMHJulianoR & HerdewijnP (2004) Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. Biochemical Pharmacology68: 403–407.
10.
BardosTJ (1974) Antimetabolites: Molecular design and mode of action. Topics in Current Chemistry52: 63–98.
11.
BardosTJSchinaziRFLingK-HJ & HeiderAR (1992) Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy36: 108–114.
12.
BellonLBarascutJ-LMauryGDivitaGGoodyR & ImbachJL (1993) 4′-Thio-oligo-β-d-ribonucleotides: Synthesis of β-4′-thiooligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase. Nucleic Acids Research21: 1587–1593.
BlackDREcksteinFDe ClercqE & MeriganTC (1972) Studies on the toxicity and antiviral activity of various polynucleotides. Antimicrobial Agents & Chemotherapy3: 198–206.
15.
BlackPLMcKinnonKMWoodsenSL & UsseryMA (1993) Antiviral activity of a synthetic double-stranded polyribonucleotide interferon inducer in a murine AIDS retrovirus model. Annals of the New York Academy of Science685: 467–470.
16.
BlackPLMcKinnonKMWoodsenSL & UsseryMA (1996) Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZT. International Journal of Immunopharmacology18: 633–650.
17.
BravoF & SanchezMR (2003) New and re-emerging cutaneous infectious diseases in Latin America and other geographic areas. Dermatologic Clinics21: 655–668.
18.
BrikAMuldoonJLinY-CElderJHGoodsellDSOlsonAJFokinVVSharplessKB & WongC-H (2003) Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. Chembiochem: A European Journal of Chemical Biology4: 1246–1248.
19.
BroomADAgrawalVKTutondaMGFainHD & BuckheitRW (1995) Unusual single-stranded polyribonucleotides as potent anti-HIV agents. Journal of Medicinal Chemistry38: 3253–3257.
20.
BrunoMRosselliSPibiriIKilgoreN & LeeK-H (2002) Anti-HIV agents derived from the ent-Kaurane diterpenoid linearol. Journal of Natural Products65: 1594–1597.
21.
BurnsWHSaralRSantosGWLakinOLLietmanPSMcLarenC & BarryDW (1982) Isolation and characterisation resistant Herpes simplex virus after acyclovir therapy. Lancet1: 421–423.
22.
CapaccioliSDi PasqualeGMiniEMazzeiT & QuattroneA (1993) Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochemical & Biophysical Research Communications197: 818–825.
23.
CarterWAPithaPM & MarshallWTazawaITazawaS & Ts'oPOP (1972) Structural requirements of the rIΣMrCn complex for induction of human interferon. Journal of Molecular Biology70: 567–587.
24.
CarterWABrodskyIPellegrinoMGHenriquesHFParentiDMSchlufRSRobinsonWEVolskyDJPaxtonHKarikuKSuhadolnikRJStrayerDRLewinMEinckLSimonGLScheibRGMontefioriDCMitchellWMPaulDMeyerWAIIIReichenbachN & GillespieDH (1987) Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet1: 1286–1292.
25.
ChandraPEbnerUSteelLKLaubeHGerickeDMildnerBBardosTJHoYK & GotzA (1977) Molecular approaches to inhibit oncogenesis by RNA tumor viruses. Annals of the New York Academy of Science284: 444–462.
26.
ChouSEriceAJordanMCVercellottiGMMichelsKRTalaricoCLStanatSC & BironKK (1995) Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. Journal of Infectious Diseases171: 576–583.
27.
CottenMOberhauserBBrunarHHolznerAIssakidesGNoeCRSchaffnerGWagnerE & BirnstielM (1991) 2′-O-methyl, 2′-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event. Nucleic Acids Research19: 2629–2635.
28.
CraneLRLevyHB & LernerAM (1982) Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes. Antimicrobial Agents & Chemotherapy21: 481–485.
29.
DaumTEngelsJWMagMMuthJLuckingSSchroderHCMetthesonE & MullerWE (1992) Antisense oligodeoxynucleotide: Inhibitor of splicing of mRNA of human immunodeficiency virus. Intervirology33: 65–75.
De ClercqEBilliauAHattoriM & IkeharaM (1975) Inhibition of oncornavirus functions by poly (2-methylinosinic acid). Nucleic Acids Research2: 2305–2313.
32.
De ClercqE (1982) Design of nucleoside, oligonucleotide and polynucleotide analogues as antiviral agents. Nucleic Acids Symposium Series11: 203–206.
33.
DeLongRKYooHAlahariSKFisherMShortSMKangSHKoleRJanoutVReganSL & JulianoRL (1999) Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Research27: 3334–3341.
34.
DiabataMEnzingerEMMonroeJEKilkuskieREFieldAK & MulderC (1996) Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication. Antiviral Research29: 243–260.
35.
DokkaS & RojanasakulY (2000) Novel nonendocytotic delivery of antisense oligonucleotides. Advanced Drug Delivery Reviews44: 35–49.
36.
DrostenCGuntherSPreiserWvan der WerfSBrodtH-RBeckerSRabenauHPanningMKolesnikovaLFouchierRAMBergerABurguièreA-MCinatlJEickmannMEscriouNGrywnaKKrammeSManuguerraJ-CMullerSRickertsVStumerMViethSKlenkH-DOsterhausADMESchmitzH & DoerrHW (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England Journal of Medicine348: 1967–1976.
37.
DuelandAN (1996) Latency and reactivation of varicella zoster virus infections. Scandinavian Journal of Infectious Diseases Supplement100: 46–50.
38.
EcksteinF (2000) Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?Antisense Nucleic Acid Drug Development10: 117–121.
EsseyRJMcDougallBR & RobinsonWEJr (2001) Mismatched double-stranded RNA (polyIPolyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Research51: 189–202.
41.
FauciAS (2001) Infectious diseases: Considerations for the 21st century. Clinical Infectious Diseases32: 675–685.
42.
FieldAKTytellAALampsonGP & HillemanMR (1967) Inducers of interferon and host resistance II. Multistranded synthetic polynucleotide complexes. Proceedings of the National Academy of Sciences, USA58: 1004–1010.
43.
FieldAKTytellAAPipernoELampsonGPNemesMM & HillemanMR (1972) Poly I:C, an inducer of interferon and interference against virus infections. Medicine51: 169–174.
44.
FilmoreD (2004) Assessing antisense. Modern Drug Discovery7: 49–50.
45.
FreulonIRocheA-CMonsignyM & MayerR (2001) Delivery of oligonucleotides into mammalian cells by anionic peptides: Comparison between monomeric and dimeric peptides. Biochemistry Journal354: 671–679.
46.
FuZFWickstromEJiangMCorisdeoSYangJDietzscholdB & KoprawskiH (1996) Inhibition of rabies virus infection by an oligodeoxynucleotide complementary to rabies virus genomic RNA. Antisense Nucleic Acid Drug Development6: 87–93.
47.
FurdonPJDominskiZ & KoleR (1989) RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Research17: 9193–9204.
48.
FurtadoMRCallawayDSPhairJPKunstmanKJStantonJLMacKenCAPerelsonAS & WolinskySM (1999) Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New England Journal of Medicine340: 1614–1621.
49.
GalderisiUCascinoA & GiordanoA (1999) Antisense oligonucleotides as therapeutic agents. Journal of Cellular Physiology181: 251–257.
50.
GearyRSWatanabeTATruongLFreierSLesnikEASioufiNBSasmorHManoharanM & LevinAA (2001) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. Pharmacology & Experimental Therapeutics296: 890–897.
51.
GaoW-YSteinCACohenJSDutschmanGE & ChengY-C (1989) Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2 induced DNA polymerase. Journal of Biological Chemistry264: 11521–11526.
52.
GaoW-YHanesRNVazquez-PaduaMASteinCACohenJS & ChengY-C (1990) Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrobial Agents & Chemotherapy34: 808–812.
53.
GillespieDHubbellHRCarterWAMidgettePElsasserWMullaneyR & StrayerDR (1994) Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements. In Vivo8: 375–381.
54.
GopalsamyALimKEllingboeJWMitsnerBNikitenkoAUpeslacisJMansourTSOlsonMWBebernitzGAGrinbergDFeldBMoyFJ & O'ConnellJ (2004) Design and synthesis of 1,6-naphthalene derivatives as selective HCMV protease inhibitors. Journal of Medicinal Chemistry47: 1893–1899.
55.
GrilloneLR & LanzR (2001) Fomiversen. Drugs of Today37: 245–255.
56.
GroseC (2004) Avian influenza virus infection of children in Vietnam and Thailand. Pediatric Infectious Disease Journal23: 793–794.
57.
GryaznovSMLloydDHChenJ-KSchultzRGDeDionisioLARatmeyerL & WilsonWD (1995) Oligonucleotide N3′(P5′ phosphoramidates. Proceedings of the National Academy of Sciences, USA92: 5798–5802.
58.
HamerDH (2004) Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Current HIV Research2: 99–111.
59.
HenleyE (2003) Prevention and treatment of influenza. Journal of Family Practice52: 883–887.
60.
HochgurtelMBiesingerRKrothHPiechaDHofmannMWKrauseSSchaafONicolauC & EliseevAV (2003) Ketones as building blocks for dynamic combinatorial libraries: Highly active neuraminidase inhibitors generated via selection pressure of the biological target. Journal of Medicinal Chemistry46: 356–358.
61.
HolmlundJT (2003) Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Annals of the New York Academy of Science1002: 244–251.
HussainMShchepinovMSohailMBenterIFHollinsAJSouthernEM & AkhtarS (2004) A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. Journal of Controlled Release99: 139–155.
HydeRMBroomAD & BuckheitRW (2003) Antiviral amphipathic oligo- and polyribonucleotides: Analogue development and biological studies. Journal of Medicinal Chemistry46: 1878–1885.
66.
IyerRPJinYRolandAMorreyJDMounirS & KorbaB (2004) Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents. Antimicrobial Agents & Chemotherapy48: 2199–2205.
67.
JepsonJSSorensenMD & WengelJ (2004) Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides14: 130–146.
68.
JohnsonTOHuaYLuuHTBrownELChanFChuSSDragovichPSEastmanBWFerreRAFuhrmanSAHendricksonTFMaldonadoFCMatthewsDAMeadorJWIIIPatickAKReichSHSkalitzkyDJWorlandSTYangM & ZalmanLS (2002) Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. Journal of Medicinal Chemistry45: 2016–2023.
69.
KalotaAShetzlineSE & GewirtzAM (2004) Progress in the development of nucleic acid therapeutics for cancer. Cancer Biology & Therapy3: 4–12.
70.
Kibler-HerzogLZonGUznanskiBWhittierG & WilsonWD (1991) Dublex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Research19: 2979–2986.
71.
KimKTrangPUmamotoSHaiR & LiuF (2004) RNase P ribozyme inhibits cytomegalovirus replication by blocking the expression of viral capsid proteins. Nucleic Acids Research32: 3427–3434.
72.
KirkwoodJ (2002) Cancer immunotherapy: The interferon-alpha experience. Seminars in Oncology29: 18–26.
73.
KungMPHoYK & BardosTJ (1982) 5-Mercaptopolyuridylic acid (MPU), a potent inhibitor of the reverse transcriptase from avian myeloblastosis virus. Research Communications in Pathology & Pharmacology36: 215–228.
74.
LampsonGPFieldAKTytellAA & HillemanMR (1981) Poly I:C/poly-l-lysine: Potent inducer of interferons in primates. Journal of Interferon Research1: 539–549.
75.
LedergerberBEggerMOpravilMTelentiAHirschelBBattegayMVernazzaAPSudrePFleppMFurrerHFrancioliP & WeberR (1999) Clinical progression and virological failure of highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet353: 863–868.
76.
LemaitreMBBayardB & LebleuB (1987) Specific antiviral activity of a poly (L-lysine)-conjugated oligodeoxyibonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proceedings of the National Academy of Sciences, USA84: 648–652.
77.
LeumannCJ (2002) DNA analogues: From supramolecular principles to biological properties. Bioorganic Medicinal Chemistry19: 841–854.
78.
LevinAA (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochemica Biophysica Acta1489: 69–84.
79.
LevyHBBaerGBaronSBucklerCEGibbsCJIadarolaMJLondonWT & RiceJ (1975) A modified polyriboinosinic acid complex that induces interferon in primates. Journal of Infectious Diseases132: 434–439.
80.
LevyHBLondonWFuccilloDABaronS & RiceJ (1976) Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic-polyribocyticylic acid-poly-l-lysine. Journal of Infectious Diseases133(Suppl): A256–259.
81.
LevyHB & LvovskyE (1978) Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. Journal of Infectious Diseases137: 78–81.
82.
LewisJGLinK-YKothavaleAFlanaganWMMatteucciMDDePrinceRBMookRAJrHendrenRW & WagnerRW (1996) A serum-resistant cytofectin for cellular delivery of antisense olibodeoxynucleotides and plasmid DNA. Proceedings of the National Academy of Sciences, USA93: 3176–3181.
83.
LeyssenPDrostenCPaningMCharlierNPaeshuyseJDe ClercqE & NeytsJ (2003) Interferon, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrobial Agents & Chemotherapy47: 777–782.
84.
LiGLisziewiczJSunDZonGDaeflerSWong-StaalFGalloRC & KlotmanME (1993) Inhibition of rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the rev-responsive element. Journal of Virology67: 6682–6688.
85.
LindsayHLTrownPWBrandtJ & ForbesM (1969) Pyrogenicity of Poly I. Poly C in rabbits. Nature223: 717–718.
86.
LysikMA & Wu-PongS (2003) Innovations in oligonucleotide drug delivery. Journal of Pharmaceutical Sciences92: 1559–1573.
87.
LisziewiczJSunDWeicholdFFThierryARLussoPTangJGalloRC and AgrawalS (1994) Antisense oligodeoxynucleotide phosphorothioate complementary to gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proceedings of the National Academy of Sciences, USA91: 7942–7946.
88.
LundOSNielsenJO & HansenJE (1995) Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev. Antiviral Research28: 81–91.
89.
LvovskyELevinePHFuccilloDAblashiDVBengaliZHArmstrongGR & LevyHB (1981) Epstein-Barr virus and herpesvirus saimiri: Sensitivity to interferons and interferon inducers. Journal of the National Cancer Institute66: 1013–1019.
90.
ManoharanM (1999) 2′-Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration and conjugation. Biochimica Biophysica Acta1489: 117–130.
91.
McCaffreyAPMeuseLKarimiMContagCH & KayMA (2003) A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Heptology38: 503–508.
92.
McCownMDiamondMS & PekoszA (2003) The utility of siRNA transcripts produced by RNA polymerase in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology313: 514–524.
93.
MeriganTC (1970) Interferon stimulated by double stranded RNA. Nature228: 219–222.
94.
MilhavetODevinSG & MattsonMP (2003) RNA interference in biology and medicine. Pharmacological Reviews55: 629–648.
MilliganJFMatteucciMD & MartinJC (1993) Current concepts in antisense drug design. Journal of Medicinal Chemistry36: 1836–1923.
97.
Miyano-KurosakiNBarnorJSTakeuchiHOwadaTNakashimaHYamamotoNMatsukakiTShimadeF & TakakuH (2004) In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes. Antiviral Chemistry & Chemotherapy15: 93–100.
98.
MoniaBPLesnikEAGonzalezCLimaWFMcGeeDGuinossoCJKawasakiAMCookPD & FreierSM (1993) Evaluation of 2′-modified oligonucleotides contaning 2′-deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry268: 14514–14522.
99.
MontefioriDC & MitchellWM (1987) Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proceedings of the National Academy of Sciences, USA84: 2985–2989.
100.
MorensDMFolkersGK & FauciAS (2004) The challenge of emerging and re-emerging infectious diseases. Nature430: 242–249.
101.
MoriyaKMatsukuraMKurokawaK & KoikeK (1996) In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochemica Biophysica Acta218: 217–223.
102.
MorreyJDDayCWJulanderJGBlattLMSmeeDF & SidwellRW (2004) Effect of interferon-alpha and interferon inducers on West Nile virus in mouse and hamster models. Antiviral Chemistry & Chemotherapy15: 101–109.
103.
MorrisMCVidalPChaloinLHeitzF & DivitaG (1997) A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Research25: 2730–2736.
104.
MoultonHGHaseMCSmithKM & IversonPL (2003) HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense & Nucleic Acid Drug Development13: 31–43.
105.
NeumanBWSteinDAKroekerADPaulinoADMoultonHMIversenPL & BuchmeierMJ (2004) Antisense morpholino-oligomers directed against the 5′ end of genome inhibit coronavirus proliferation and growth. Journal of Virology78: 5891–5899.
106.
NulfCJ & CoreyD (2004) Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Research32: 3792–3798.
O'MarroSDArmstrongJAAsuncionCGueverraL & HoM (1992) The effect of combinations of Ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro. Antiviral Research17: 169–77.
109.
OpalinskaJBKalotaAGiffordLKLuPJenKYPradeepkumarPIBarmanJKimTKSwiderCRChattopadhyayaJ & GewirtzAM (2004) Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Research32: 5791–5799.
110.
OrrRM (2001) Technology evaluation: Fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Current Opinion in Molecular Therapy3: 288–294.
PatelR (2002) Progress in meeting today's demands in genital herpes: An overview of current management. Journal of Infectious Diseases186(Suppl 1): S47–S56.
113.
PawlotskyJM (2003) The nature of interferon-alpha resistance in hepatitis C virus infection. Current Opinion in Infectious Disease16: 587–592.
114.
PeracchiA (2004) Prospects for antiviral ribozymes and deoxyribozymes. Reviews in Medical Virology14: 47–64.
115.
PetersCJReynoldsJASloneTWJonesDE & StephenEL (1986) Prophylaxis of rift valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Research6: 285–297.
116.
PetersonLR & RoehrigJT (2001) West nile virus: A reemerging global pathogen. Emerging Infectious Diseases7: 611–614.
117.
PichonCFreulonIMidouxPMayerRMonsignyM & RoucheAC (1997) Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Development7: 335–343.
118.
PintoAJMorahanPS & BrintonMA (1988) Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses. International Journal of Immunopharmacology10: 197–209.
119.
PirolloKFRaitASleerLS & ChangEH (2003) Antisense therapeutics: From theory to clinical pratice. Pharmacology & Therapeutics99: 55–77.
120.
PrakashTPManoharanMKawasakiAMFraserASLesnikEASioufiNLeedsJMTeplovaM & EgliM (2002) 2′-O-[2-(methylthio)ethyl]-modified oligonucleotide: An analogue of 2′-O-[2-(methoxy)-ethyl]-modified oligonucleotide with improved protein binding properties and high binding affinity to target RNA. Biochemistry41: 11642–11648.
121.
PradeepkumarPIAmirkhanovNV & ChattopadhyayaJ (2003) Antisense oligonucleotides with oxetane-constrained cytidine enhance heteroduplex stability, and elicit satisfactory RNase H response as well as showing improved resistance to both exo and endonucleases. Organic & Biomolecular Chemistry1: 81–92.
122.
PrasadVHashimSMukhopadhyayABasuSK & RoyRP (1999) Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: Enhanced antiviral activity of a vesicular stomatitus virus-specific antisense oligonucleotide. Antimicrobial Agents & Chemotherapy43: 2689–2696.
123.
PraterCE & MillerPS (2004) 3′-Methylphosphonate-modified oligo-2′-O-methylribonucleotides and their Tat peptide conjugates: Uptake and stability in mouse fibroblasts in culture. Bioconjugate Chemistry15: 498–507.
124.
PurcellRHLondonWTMcAuliffeVJPalmerAEKaplanPMGerinJLWagnerJPopperHLvovskyEWongDC & LevyHB (1976) Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet2: 757–761.
125.
ShawRamsay BDobrikovMWangXWanJHeKLinJ-LLiPRaitVSergueevaZA & SergueevD (2003) Reading, writing and modulating generic information with boranophosphate mimics of nucleotides, DNA, and RNA. Annals of the New York Academy of Science1002: 12–29.
SakaiHMoriguchiTSuzukiHMatsukuraM & ShinozukaK (2001) Investigation of antisense DNA having C-5 polyamine substituted 2′-deoxyuridine derivatives. Nucleic Acids Research Supplement1: 127–128.
128.
SampathkumarPTemesgenZSmithTF & ThompsonRL (2003) SARS: Epidemiology, clinical presentation, management, and infection control measures. Mayo Clinic Proceedings78: 882–890.
129.
SeiSYangQ-EO'NeilDYoshimuraKNagashimaK & MitsuyaH (2000) Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. Journal of Virology74: 4621–4633.
130.
SidwellRWHuffmanJHBarnardDLSmeeDFWarrenRPChirigosMAKendeM & HugginsJ (1994) Antiviral and immunomodulating inhibitors of experimentally-induced punta toro virus infections. Antiviral Research25: 105–122.
131.
SinghIPCoppenhaverDHSarzottiMSriyuktasuthPPoastJLevyHB & BaronS (1989) Postinfection therapy of arbovirus infections in mice. Antimicrobial Agents & Chemotherapy33: 2126–2131.
132.
StarkGRKerrIMWilliamsBRGSilvermanRH & SchreiberRD (1998) How cells respond to interferons. Annual Review of Biochemistry67: 227–264.
133.
SteinDFosterEHuangSBWellerD & SummertonJ (1997) A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Development7: 151–157.
134.
SteinCAMatsukuraMSubasingheCBroderS & CohenJS (1989) Phophorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Research & Human Retroviruses5: 639–646.
135.
StephenELSammonsMLPannierWLBaronSSpertzelRO & LevyHB (1977) Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). Journal of Infectious Diseases136: 122–126.
136.
StephenELHilmasDELevyHB & SpertzelRO (1979) Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. Journal of Infectious Diseases139: 267–272.
137.
StephensonML & ZamecnikPC (1978) Inhibition of rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proceedings of the National Academy of Sciences, USA75: 285–288.
138.
StringfellowDA & WeedSD (1980) Interferon induction by and toxicity of polyriboinosinic acid [poly(rI)] Σpolyribocytidylic acid [poly (rC)], mismatched analog poly (rI) Σpoly [r(C12uracil)n], and poly r(I) poly (rC) L-lysine complexed with carboxymethylcellulose. Antimicrobial Agents & Chemotherapy17: 988–992.
139.
StuartDD & AllenTM (2000) A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochemica Biophysica Acta1463: 219–229.
140.
SummertonJ & WellerD (1997) Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Development7: 187–195.
141.
SummertonJ (1999) Morpholino antisense oligomers: The case for an RNAse H-independent structural type. Biochemica Biophysica Acta1489: 141–158.
142.
TackeFGehrkeCLueddeTHeimAMannsMP & TrautweinC (2004) Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. Journal of Virology78: 8524–8535.
143.
ThompsonKAStrayerDRSalvatoPDThompsonCEKlimasNMolaviAHamillAKZhengZVenturaD & CarterWA (1996) Results of a double blind placebo-controlled study of the double stranded RNA drug polyI:polyC12U in the treatment of HIV infection. European Journal of Clinical Microbiology & Infectious Diseases15: 580–587.
144.
TutondaMGFainHDBuckheitRW & BroomAD (1997) The role of hydrophobic versus hydrophilic base character in the anti-HIV activity of purine-containing polyribonucleotides. Nucleosides & Nucleotides16: 173–182.
145.
TutondaMGBuckheitRWAgrawalVK & BroomAD (1998) Antiviral oligo and polyribonucleotides containing selected triazolo[2,3-a] purines. Journal of Medicinal Chemistry25: 4958–4964.
146.
VandammeA-MVan LaethemK & De ClercqE (1999) Managing resistance to anti-HIV drugs. Drugs57: 3337–3361.
147.
VastolaKAHoYKBardosTJGrossmayerBJFruck-DiviakL & O'MalleyJA (1984) Poly I-mercapto poly C: Antiviral, anticellular and pharmacologic effects. Research Communications in Chemical Pathothogy & Pharmacology45: 407–419.
148.
De VeerMJHolkoMFrevelMWalkerEDerSParanjapeJMSilvermanRH & WilliamsBRG (2001) Functional classification of interferon-stimulated genes identified using microarrays. Journal of Leukocyte Biology69: 912–920.
149.
VerbeureBLescrinierEWangJ & HerdewijnP (2001) RNAse H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA). Nucleic Acids Research29: 4941–4947.
150.
WintersTA (2000) Gene targeted agents: New opportunities for rational drug development. Current Opinion in Molecular Therapy2: 670–681.
151.
WodarzD & LloydAL (2004) Immune responses and the emergence of drug-resistant virus strains in vivo. Proceedings of the Royal Society of London. Series B. Biological Sciences271: 1101–1109.
152.
WongJPSaravolacEGSabudaDLevyHB & KendeM (1995) Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrobial Agents & Chemotherapy39: 2574–2576.
153.
WHO (2004a) The World Health Report 2004: Changing History (annex 1). Geneva: WHO.
154.
WHO (2004b) Hepatitis E in Sudan. Geneva: WHO.
155.
YooBHBochkarevaEBochkarevAMouT-C & GrayDM (2004) 2′-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Research32: 2008–2016.
156.
WuJ & NandamuriKM (2004) Inhibition of hepatitis viral replication by siRNA. Expert Opinion in Biological Therapy4: 1649–1659.
157.
ZamecnikPC & StephensonML (1978) Inhibition of rous sarcoma virus replication and cell translation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences, USA75: 280–284.
158.
ZamecnikPCGoodchildJTaguchiY & SarinPS (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonnucleotides complementary to viral RNA. Proceedings of the National Academy of Sciences, USA83: 4143–4146.
159.
ZhouCBahnerICLarsonGPZaiaJARossiJJ & KohnEB (1994) Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Genes149: 33–39.
